Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaxelis long-term hepatitis B protection challenge study in previously vaccinated children
2020-000126-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Recombivax HB in hepatitis B (HBV), sponsored by Merck & Co. Primary endpoint: Percentage of participants with anti-HBs >=10 mIU/mL 30 days after HBVAXPRO. Started Jun 2020; status: completed.
02
Drugs
Recombivax HB
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2020-000126-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000126-26.